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(http://creativecommo(75 years) has recently been found positive on both sides of the Atlantic. We hypothesized that
higher levels of CRP and fibrinogen are related to worse episodic memory throughout later life
(50 years).
Methods: Data are drawn from older Britons free of dementias in the English Longitudinal Study of
Aging 2004–2013. We applied growth trajectory models to repeated observations of episodic
memory, CRP, and fibrinogen levels (and sociodemographic confounders). We accounted for practice
effects in repeated tests of cognition.
Results: Higher levels of both inflammatory markers were associated with worse episodic memory,
where a fibrinogen effect is evident throughout later life (coefficient20.154; 95% confidence interval
[CI] 20.254 to 20.054). Most importantly, the CRP effect is strongly negative among the older old
group (coefficient 20.179; CI 20.320 to 20.038).
Discussion: Higher levels of fibrinogen are detrimental to older people’s cognition, and among the
older old, raised CRP levels are comparably deleterious. Repeated measures of inflammation can be
considered in clinical practice as part of a response to the challenge of dementias.
 2016 The Author. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: C-reactive protein; Fibrinogen; Episodic memory; England1. Introduction
Dementias have a long period of preclinical development
[1,2]. With increase in life expectancy of the aging
population, it is all the more important to understand early
changes in cognitive function that presage cognitive
impairment. Systemic inflammatory markers have been
investigated for this purpose in middle aged and older
people and have been found to be associated with many
cognitive abilities including episodic memory, executive
function, and global cognition [3–12].
Two biomarkers are often used in studies of cognition and
inflammation: fibrinogen and C-reactive protein (CRP).
Epidemiologic, genetic, or pharmacologic studies on thethor. Tel:144 161 3066932; Fax:144 161 2754721.
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he Author. Published by Elsevier Inc. on behalf of the Alzhe
ns.org/licenses/by/4.0/).relationship of fibrinogen to cognition suggest that higher
levels of fibrinogen in the peripheral system are related to
worse cognition [13–16]. In the Aspirin for Asymptomatic
Atherosclerosis Trial of older people in Scotland (aged
50–80 years), higher levels of baseline fibrinogen and CRP
were associated with worse cognition during follow-up in
cross-sectional design [9]. Also in Scotland, the Edinburgh
Artery Study (aged 55–74 years) found that higher levels
of fibrinogen at baseline predicted cognition deficits 14 years
later in cross-sectional design [8]. The baseline levels were
also associated with cognitive decline in change-scores
longitudinal design, where only cognition is repeatedly
measured.
Epidemiologic studies of the link between CRP and
cognition have found results that cover the negative to
positive spectrum of associations. In the Rotterdam Study
(aged 55–106 years), higher levels of CRP at baseline
were associated with worse cognition in cross-sectionalimer’s Association. This is an open access article under the CC BY license
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decline in cognitive function in change-scores longitudinal
design [11]. Across the Atlantic, the Health, Aging, and
Body Composition study found that being in the highest
tertile of CRP levels at baseline had the same odds as being
in the lower tertiles when predicting 4 years cognitive
decline in change-scores longitudinal design [4]. Weak
evidence is also found in the British Whitehall II study
(mean age 48, standard deviation [SD] 6 years) where levels
of CRP at baselinewere associated with worse reasoning and
vocabulary functions in cross-sectional design but were
not associated with cognitive decline in change-scores
longitudinal design [6]. Remarkably in the older old (age
75 years), raised CRP is associated with better cognition
[10,17], suggesting some genetic factors are responsible;
see also [2]. An active inflammatory system may be found
protective, delaying cognitive decline among the older old.
From a clinical perspective, this literature on peripheral
inflammation has yet to bear fruit. Some are equivocal about
the possibility [16], but others are less sanguine about the use
of blood-based biomarkers in practice [11]. Such a viewmay
be hasty given the weaknesses in the literature. First, it is
unclear whether the positive relationship between
inflammation and cognition applies to the younger old
(50–75 years), a group of some importance given the
well-known long duration of development of severe
cognitive impairment. Second, many of these studies used
one baseline measure of inflammation against repeated
measures of cognition, effectively explaining change
scores or decline as the dependent variable (change-scores
longitudinal design). This poses two problems, one of which
applies to any outcome (dilution bias), whereas the another
applies specifically to cognition (practice effect). As is
widely acknowledged in longitudinal studies, such
change-scores design is susceptible to regression dilution
bias [2–8,11,18]. It is possible that prospectively collected
repeated measures of both cognition and biomarkers will
modify the results mentioned.
In addition, a well-known threat to inference in longitudi-
nal studies of cognition arises from practice effects [19–22].
Apparent change in the test scores at two time points is partly
down to the fact that participants have completed the same
tests before. In the pages of this journal, it has been
suggested that practice effects are “large, pervasive and
under-appreciated” [22]. So in change-scores longitudinal
design, if dilution bias can compromise analysis of any
health outcomes, including physical and cognitive functions,
practice effects can additionally compromise cognitive
outcomes. Together, they render many biomarkers studies
of cognitive decline doubly unsafe and unsatisfactory.
Finally, cognition in older people is maintained through
mechanisms involving various biological and social factors.
Careful accounting of cognitive deficits in later life requires
social factors to be considered as well.
To address these weaknesses, this study used the
English Longitudinal Study of Aging (ELSA) 2004–2013,a nationally representative prospective longitudinal study
of older people (50 years) with repeated measures of the
exposures, the outcomes and other demographic, economic,
chronic conditions, and health behaviors as well as social
factors. This study aimed to test two hypotheses. First, levels
of high sensitivity CRP are related to worse episodic
memory in younger old (,75 years) and in older old
(75 years) Britons. Second, analogously, levels of
circulating fibrinogen are independently related to worse
episodic memory.
This measure of cognition is an important and popular
measure in research on cognitive aging since it is easy to
collect, easy to understand, and at the same time has been
shown to be instrumental in life changing decisions such
as pension decisions [23,24,25]. So not only does it enable
research replication or cross-country comparison, it is also
immediately relevant.2. Materials and methods
2.1. English Longitudinal Study of Aging
The ELSA is the primary resource for a nationally
representative aging study of the English older population;
it was started in 2002 and subsequent waves follow
biennially. In every even-numbered wave, a nurse
assessment is given to collect biomedical information. The
repeated biomarkers and episodic memory variables are,
therefore, available from 2004 to 2005, 2008 to 2009, and
2012 to 2013 waves. The data are freely available from the
UK Data Archive (www.data-archive.ac.uk) as study
number 5050. More details of the study are given elsewhere
[26–31].2.2. Ethics
Ethical approval for all the ELSA waves was granted
from the National Research and Ethics Committee of
the UK National Health Service www.nres.nhs.uk. The
University of Manchester’s institutional review board has
exempted this study because it used publicly available
anonymized secondary data.2.3. Dependent variable
The dependent variable is episodic memory, the sum of
delayed and immediate recall, available in all waves [23].
It is notable that this variable is also available in its sister
study, the US Health and Retirement Study [32].2.4. Independent variables
Information from respondents aged50 to 89yearswas used
because age is capped at 90 years in ELSA. Demographic co-
variates include sex, age and squared-age to capture possible
curvilinear trajectories [20,21,33]. To capture practice effects,
an indicator variable is constructed, coding 1 if a respondent
Table 1
Descriptive statistics of the analytic sample
Variable
Analytic sample,
n 5 14,180 person-year
Episodic memory (mean, SD) 10.5, 3.5
High sensitivity CRP, mg/L (mean, SD) 2.6, 2.3
Fibrinogen, g/L (mean, SD) 3.0, 1.0
Age, y (mean, SD) 67.3, 8.4
Sex, women (n, %) 7947, 54.4
Education, college (n, %) 4571, 31.3
Less than college degree (n, %) 10,040, 68.7
Married or cohabit (n, %) 10,248, 70.1
Not married or cohabit (n, %) 4363, 29.9
Wealth tertile, bottom (n, %) 4069, 27.9
Middle tertile (n, %) 5078, 34.8
Richest tertile (n, %) 5464, 37.4
Ethnicity, Caucasian (n, %) 14,360, 98.3
Ethnic minority (n, %) 251, 1.7
Occupation, prof-managerial (n, %) 5569, 38.1
Intermediate (n, %) 3469, 23.7
Routine manual (n, %) 5573, 38.1
Social contact,  once a week (n, %) 7584, 51.9
Physical problems (mean, SD) 1.9, 2.8
Hypertensive (n, %) 6072, 41.6
Lung disease (n, %) 848, 5.8
Diabetics (n, %) 1223, 8.4
Cancer (n, %) 1214, 8.3
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0 otherwise; following others [21,34].
Blood samples were collected in three waves and kept
deep-frozen until analysis at the Newcastle NHS hospital
laboratory. Plasma samples were analyzed for fibrinogen
using an ACL TOP CTS analyzer. The change in light
transmission caused by the conversion of soluble fibrinogen
in plasma to cross-linked insoluble fibrin is monitored by the
analyzer, and the clotting time threshold is determined to be
37% of the total change. The clotting time is directly related
to the concentration of fibrinogen in the plasma and this time
is converted to concentration in g/L. Plasma samples were
also analyzed for high sensitivity CRP, applying a
particle-enhanced immunoturbidimetric assay, using Roche
Modular P analyzer. CRP in the sample reacts specifically
with anti-human CRP antibodies coated on the latex
particles to yield insoluble aggregates. The turbidimetric
absorbance of these aggregates is proportional to the CRP
concentration in mg/L in the sample. Because CRP
distribution is skewed, its log transform is used.
Cognitive functions are known to be affected by physical
function problems. All three dimensions of physical
function are used in a total scores of physical function
problems, including (instrumental) activities of daily living,
mobility, and muscle functions [27]. Like other health
functions, cognitive functions are also shaped by social
determinants of health [26,35,36]. They include threefold
social class (managerial, intermediate, and routine-manual
as reference), wealth tertiles (top, middle, and bottom as
reference), marital status (married/cohabiting and other as
reference), education (some college and high school or
less as reference), and ethnicity (minority and Caucasian
white as reference). Social contact is entered as an indicator
of making contact with friends once a week or more by
email, by phone, in writing, or in person.
Based on positive medical history (self-report of “has
been diagnosed by professionals”), a series of indicators
about chronic conditions are also included, covering
diabetes, cancer, hypertension, lung disease, heart condition,
and stroke. Depression score is elicited using the Center for
Epidemiologic Studies Depression scale (eight items) and is
entered as a continuous variable.
Behavioral risk factors known to be effective in
cross-sectional studies include smoking (current smoker
and not current smoker as reference), drinking (days in a
week having a drink), and physical exercise (rigorous, mod-
erate physical exercise and mild or less as reference) [24].Heart condition (n, %) 2463, 16.9
Stroke (n, %) 487, 3.3
CES-D 4 (n, %) 1752, 12.0
Current smoker (n, %) 9035, 61.8
Drink regularly (n, %) 12,042, 82.4
Exercise moderately (n, %) 11,586, 79.3
Exercise vigorously (n, %) 4546, 31.1
Abbreviations: SD, standard deviation; CRP, C-reactive protein; CES-D,
Center for Epidemiologic Studies Depression scale; ELSA, English
Longitudinal Study of Aging.Source: ELSA 2004–2014.2.5. Statistical analysis
Following theoretical [33] and empirical [20,37] accounts
of cognitive aging in Britain, a quadratic trajectory model is
applied with random intercepts and random age slopes. This
model, also known as a random-effects model or growth curve
model, accounts for variations within individuals and across
individuals. This model also gives consistent estimates ofthe effects of biomarkers when some participants leave the
study, assuming missingness at random. This assumption
means that, conditional on all the extensive covariates being
accounted for, the differences between the dropouts and the
stayers are due to mere chance [20]. We built a sequence of
two models with increasing completeness addressing the
gaps mentioned. First, the inflammations model included (in
addition to the extensive confounders) the two key exposures
of fibrinogen and log CRP levels. Second, to check whether
among the older old the associations were reversed, the inter-
actions model had two additional factors (an interaction be-
tween age 75 years and fibrinogen levels; analogously
with age75 years and log-CRP levels). This cutoff was cho-
sen following the literature [10,17]. All analyses are done in
Stata 13 (StataCorp LP, College Station, TX, USA).3. Results
The analytic sample is made up of those with complete
covariates (Table 1) and has 54.4% females and 45.6%males
with age ranging from 52 to 89 (mean 5 67.3 years,
SD 5 8.4 years). Education can obscure age-related change
in cognition due to education conferring test taking abilities,
Table 2
Inflammatory markers and episodic memory (coefficients and confidence




0.033 (20.036 to 0.101)
CRP and age 75 20.179* (20.320 to 20.038)
Fibrinogen 20.149** (20.248
to 20.050)
20.154** (20.254 to 20.054)
Fibrinogen and
age 75
0.031 (20.039 to 0.102)
N 14,180 14,180
R2 0.25 0.25
Abbreviations: ELSA, English Longitudinal Study of Aging; CRP,
C-reactive protein.
NOTE. Adjusted for sex, age, age2, education, wealth, occupational class,
marital status, ethnicity, social contact, physical function problems,
hypertension, lung disease, diabetes, cancer, heart conditions, stroke,
CES-D score, smoking, drinking, and exercise. Significant at 5% *, 1% **.
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inequalities in health are controlled for by also including
wealth and occupational social class. This sample has
38.1% professionals or managers and about the same
fraction held routine manual occupations. On average, the
sample member reported nearly two physical problems
(SD 5 2.8). In this description, depression score has been
grouped into two: none to 3 (88%) and 4 or more as
depressed or “case-ness” (12%). On health behaviors of
the sample, nearly four in five engaged in moderate physical
exercise at least once a week and nearly one in three reported
vigorous physical exercise during the same period.
The results from the sequence of models explaining
episodic memory are given in Table 2 (coefficients and
95% confidence intervals [CI] in parentheses). In all models,
episodic memory follows a nonlinear age trajectory
[20,21,37]. (The complete coefficients and CIs are given in
the Supplementary Material.) The baseline model shows
that higher levels of fibrinogen are associated with worse
episodic memory. The magnitudes and signs of fibrinogen
associations remain similar along the sequence of models.
Thus, in the interaction model, fibrinogen has a coefficient
of 20.154 and CI of 20.254 to 20.054. The interaction
model also shows that higher levels of CRP are associated
with worse episodic memory among the older old (coeffi-
cient 20.179; CI 20.320 to 20.038). So both fibrinogen
and CRP levels are associated with lower levels of episodic
memory, particularly among the older old.4. Discussion and conclusion
Severe cognitive impairment is known to be preceded by a
long period of preclinical development [1,38]; and the role of
repeated inflammation in this development is examined here.
In a nationally representative prospective longitudinal study,
both high sensitivity CRP and fibrinogen levels were
associated with cognitive deficits. Although the CRP effect
was observable among the older old (75 years), thefibrinogen effect was observable earlier from the middle
age (50 years).
Cognitive function, like other health outcomes [35,36], is
found to show strong social patterning along markers of
socioeconomic positions of wealth, occupation, and
education. In particular, the middle and top tertiles of
wealth distribution showed significantly higher levels of
cognitive function in later life (50 years), in fact showing
a monotone increase. A gradient is also presented with
respect to education; compared with the routine-manual class,
those with intermediate occupations showed higher levels of
cognitive function and those with managerial or professional
occupations showed still higher levels of cognitive function.
The study has some limitations. On the choice of
outcome, episodic memory is only one among many
cognitive abilities that change during cognitive aging.
Different cognitive abilities have shown different patterns
of change over time [23,39]. In parallel, different parts of
the brain are activated in carrying out different cognitive
tasks. Episodic memory, however, is important for many
day-to-day and momentous decisions in later life, such as
choosing retirement provision [25]. On the main exposure,
inflammation is a complex biological process as it is
simultaneously protective and destructive. The use of only
two inflammatory markers is clearly limited, although the
set examined here offers the advantage of examining
inflammation and hemostasis. The role of the APOE gene
is increasingly clear in the pathogenesis of dementias, but
this information is unfortunately lacking for all respondents
in this sample. This study directly entered an indicator of
practice instead of a random effect of practice [21,34] due
to the small variation over the limited (three) waves; with
more future waves, a random effect of practice can be used
instead. Finally, dropouts from longitudinal study of aging
can compromise inferences. This study responded to this
by applying random-effects models estimated using
maximum likelihood, which are known to give consistent
estimates under missing at random assumption [21].
A unique advantage of the materials used here arises from
its longitudinal design with repeated measures not only of
episodic memory but also of high sensitivity CRP and
fibrinogen. Not least, repeated measures of other risk factors
and confounders were also part of the design. Another
feature of the design is the nationally representative nature
of ELSA, which goes someway to ensuring that the patterns
of associations at work in the population can be extracted
without being unduly influenced by specific patterns in
some volunteer or selected samples.
These findings were in contrast to many conclusions in the
literature.Unlike a few studies on limited sampleswhich found
elevatedCRP tobe protective, ourdata showed this tobe poten-
tially detrimental in the national sample. If highCRP levels are
harmful for the older old, raised fibrinogen levels are harmful
for both younger and older old (before and after 75 years).
This longer pattern of fibrinogen association tallieswith results
in the animal and pharmacologic studies which elucidate the
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(BBB) and aiding inflammatory cascade [13,14].
On mechanisms involving fibrinogen and CRP in the
accumulation of cognitive deficits, much can be understood
from dementias pathology. We are not, however, suggesting
that cognitive deficits present in the data are likely to lead to
severe cognitive impairment or dementias for these groups.
Fibrinogen is the inactive precursor of fibrin, the primary
protein component of a blood clot. Fibrinogen, a large
complex molecule, is excluded from the brain by the BBB,
as part of the normal functioning of the BBB, which also
includes tight controls of communication between the
central nervous system and the circulation. BBB damage
has been found in mice with Alzheimer’s disease (AD) brain
and in patients with AD [13]. Through the increasingly
permeable BBB, fibrinogen gains access to the brain and
accumulates in the extravascular space, inducing pathology
in the nervous systems [14,15].
The BBB membrane structure is made up of special
endothelial cells; it functions to protect the central nervous
system from the peripheral system. This function can be
weakened when tight junctions between endothelial cells
are changed due to inflammation resulting in increased
BBB permeability, allowing larger molecules such as
fibrinogen to pass through the structure. Genetic and
pharmacologic studies have furnished evidence supporting
this fibrinogen and inflammation hypothesis [38].
In addition to extravascular disturbance to the brain, ce-
rebrovascular dysfunction was also presented in AD brains,
including cerebral amyloid angiopathy where amyloid-b
(Ab) is deposited as plaques in the blood vessels. Fibrin-
ogen bound to Ab is not efficiently cleared from the brain
because hemostasis is altered in AD [14]. Because the
brain needs a smooth supply of oxygen and glucose, as it
lacks long-term energy stores, the plaques damage the ce-
rebrovascular structure and compromise its function,
thereby inducing cerebral hypoperfusion. The levels of ce-
rebral hypoperfusion and the degree of dementia have been
reported [13].
Ab deposits on the walls of the blood vessels in cerebral
amyloid angiopathy not only disturb the blood flow but also
degenerate the cells of the walls and promote further
inflammation. Thus, the deposition of Ab in both
extravascular and cerebrovascular space contribute to the
neuroinflammation cascade [15,38].
Finally, peripheral immune signals can be transmitted via
the autonomic system to microglial cells in the brain. In turn,
chronic microglial activation and upregulated inflammatory
processes converge in the pathway of tau hyperphosphoryla-
tion [40]. This escalates further the neuroinflammatory
process and neuronal death, ending in irreversible tissue
damage [41]. The multiple processes involving hemostasis
and inflammation and their interaction are consistent with
the roles for fibrinogen and CRP found here.
In conclusion, the demonstration that both fibrinogen and
CRP levels are associated with cognitive deficits suggeststhat repeated measures of these blood-based, compared with
cerebrospinal fluid-based, biomarkers can be of some value
in clinical practice. Such possibility is an ally in responding
to the challenge posed by dementias in aging populations.Acknowledgments
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1. Systematic review: We searched PubMed for studies
on associations between higher levels of CRP and
fibrinogen and lower cognitive functions. The review
uncovered a lack of evidence using repeated mea-
sures of both inflammatory markers and cognitive
scores. Change-scores longitudinal design, where
change in scores of cognitive tests is regressed on
baseline biomarker levels, has given inconsistent
associations between biomarker levels and cognitive
decline.
2. Interpretation: Evidence from this study supports
some studies in the literature and shows higher levels
of CRP and fibrinogen are related to worse episodic
memory in later life, in the younger old and older
old groups. But the evidence also stands in contrast
to recent results which suggest that higher inflamma-
tion can be protective among the older old.
3. Future directions: Repeated measures of blood-based
biomarkers (including fibrinogen, high sensitivity
CRP, and interleukin 6) and multiple cognitive
functions (including executive function and fluid
intelligence) are needed to obtain consistent in-
ferences. This constitutes a low hanging fruit because
major longitudinal aging studies comparable with
English Longitudinal Study of Aging are ongoing in
the United States (Health and Retirement Study) and
Europe (Survey of Health, Ageing and Retirement in
Europe [SHARE]). Given the importance of de-
mentias, repeatedly collecting blood-based bio-
markers in these national samples may be clinically
and scientifically fruitful.
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